deferoxamine has been researched along with Infections, Respiratory in 2 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload." | 9.12 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007) |
| "Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload." | 5.12 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007) |
| "Pancytopenia is difficult to manage in patients with this disorder." | 1.32 | Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin. ( Erduran, E; Hacisalihoglu, S; Ozoran, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erduran, E | 1 |
| Hacisalihoglu, S | 1 |
| Ozoran, Y | 1 |
| Vichinsky, E | 1 |
| Onyekwere, O | 1 |
| Porter, J | 1 |
| Swerdlow, P | 1 |
| Eckman, J | 1 |
| Lane, P | 1 |
| Files, B | 1 |
| Hassell, K | 1 |
| Kelly, P | 1 |
| Wilson, F | 1 |
| Bernaudin, F | 1 |
| Forni, GL | 1 |
| Okpala, I | 1 |
| Ressayre-Djaffer, C | 1 |
| Alberti, D | 1 |
| Holland, J | 1 |
| Marks, P | 1 |
| Fung, E | 1 |
| Fischer, R | 1 |
| Mueller, BU | 1 |
| Coates, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis[NCT00067080] | Phase 2 | 195 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Clinical Importance of Treating Iron Overload in Sickle Cell Disease[NCT00981370] | Phase 3 | 1 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to 1 consented patient never started on study drug, lost to follow up) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for deferoxamine and Infections, Respiratory
| Article | Year |
|---|---|
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
1 other study available for deferoxamine and Infections, Respiratory
| Article | Year |
|---|---|
Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin.
Topics: Blood Cell Count; Bone Marrow; Child, Preschool; Deferoxamine; Disease Susceptibility; Dyskeratosis | 2003 |